Comments on: Koronis: Mutating HIV into extinction

By: Stephen Donner

Stephen Donner — Tue, 16 Jun 2009 10:42:32 +0000

http://www.koronispharma.com/news-2009-05-19.html has really good, encouraging data about both its in-vitro and in-vivo results.

By: David P. Hamilton

David P. Hamilton — Thu, 07 Feb 2008 15:46:49 +0000

Thanks for your comment. I should be doing a follow-up post soon, so stay tuned — I hope to get into some of the details you mention.

By: sam

sam — Thu, 07 Feb 2008 15:44:56 +0000

A very interesting drug indeed.I would however like to know the full animal data that is available,apart from safety issues. How did the virus behave,how long was it administered for,what is known on reservoirs and sanctuary sites-with this drug and animal trials.

By: The Futile Cycle » Blog Archive » Now Moved In!

The Futile Cycle » Blog Archive » Now Moved In! — Tue, 04 Sep 2007 20:55:58 +0000

[...] I am now moved in to my new room in graduate school. Classes have yet to start, but the weather is nice, the rooms are spacious, and the campus is very beautiful. It’s a bit weird to settle into a new campus this fall instead of returning to the old undergraduate campus, but I’m very excited about what’s to come. I’m also nervous that I’ve gotten soft during the summer, so I’m currently reviewing a bit of genetics, but in the meantime, I stumbled upon this interesting article on treating HIV by raising its mutation rate. [...]

By: VentureBeat » Best of the blogosphere on disease genetics

VentureBeat » Best of the blogosphere on disease genetics — Sun, 12 Aug 2007 19:02:43 +0000

[...] an added bonus, it also features two HIV-related posts by yours truly. Check it out. Tagged Alzheimers disease, Gene Genie, left handedness, multiple [...]

By: The Genetic Genealogist - » Gene Genie #13: Into the Future

The Genetic Genealogist - » Gene Genie #13: Into the Future — Sun, 12 Aug 2007 09:03:16 +0000

[...] Personalized medicine takes a (tiny) step forward. David Hamilton at VentureBeat discusses the FDA approval of Selzentry, a new AIDS drug from Pfizer. The drug, however, only works against a particular sub-strain of HIV which binds to a T-cell surface protein called CCR5. Most HIV strains use CXCR4 or a combination of the two. So, not only will OUR genomes be important for personalized medicine, so will the genomes of every pathogen that has infected us. David also discusses a new drug aimed at increasing HIV replication in Koronis: Mutating HIV into extinction. [...]